{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:05:38Z","timestamp":1773468338554,"version":"3.50.1"},"reference-count":43,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"crossref","award":["HR-2022-KH130591"],"award-info":[{"award-number":["HR-2022-KH130591"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Pembrolizumab is a novel immunotherapy agent that improves oncological outcomes for various cancers. This study aimed to investigate immune-related adverse events (irAEs) that occurred after neoadjuvant chemotherapy (NAC) with pembrolizumab for triple-negative breast cancer (TNBC) and to identify fatal irAEs that should be addressed before surgery under general anesthesia. Methods: A total of 82 patients who received NAC with pembrolizumab followed by surgery were reviewed based on their medical records. All irAEs during NAC were evaluated and classified into nine categories: systemic, dermatologic, central nervous, musculoskeletal, endocrine, gastrointestinal, respiratory, ocular, and hematologic systems. Clinicopathologic characteristics were compared between patients with and without irAEs, and cases in which surgery was postponed due to irAEs were reviewed and analyzed. Results: Fifty-nine patients (72.0%) experienced irAEs after NAC with pembrolizumab. The mean NAC period was 140.3 days, with a 39.8-day window to surgery. The most common and second most common irAEs were myalgia (n = 33, 40.3%) and skin rash\/dermatitis (n = 31, 37.8%), respectively. There were 1 case (1.2%) of adrenal insufficiency and 16 cases (19.5%) of thyroid dysfunction as irAEs. In 6 cases (7.3%), surgery was postponed due to irAEs [systemic (n = 2, 33.3%); endocrine (n = 3, 50.0%); increased transaminase (n = 1, 16.7%)], with a mean delay of 64.5 days (range, 57\u201380 days). Conclusions: IrAEs following NAC with pembrolizumab in TNBC were diverse and included those severe enough to affect the timing of surgery under general anesthesia. These irAEs should be monitored continuously during NAC and detected early to address them when they occur.<\/jats:p>","DOI":"10.3390\/cancers18060919","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:46:31Z","timestamp":1773326791000},"page":"919","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-Related Adverse Events in Breast Cancer Patients Who Received Neoadjuvant Chemotherapy with Pembrolizumab: What Needs to Be Managed Before Surgery"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1826-1690","authenticated-orcid":false,"given":"Jeeyeon","family":"Lee","sequence":"first","affiliation":[{"name":"School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeongju","family":"Kang","sequence":"additional","affiliation":[{"name":"School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Suk","family":"Moon","sequence":"additional","affiliation":[{"name":"School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6556-2632","authenticated-orcid":false,"given":"Taegyu","family":"Um","sequence":"additional","affiliation":[{"name":"School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Eun","family":"Choi","sequence":"additional","affiliation":[{"name":"College of Medicine, Yeungnam University, Daegu 42415, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moohyun","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8585-4982","authenticated-orcid":false,"given":"Yee Soo","family":"Chae","sequence":"additional","affiliation":[{"name":"School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0066-4109","authenticated-orcid":false,"given":"Soo Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jung","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Medicine, Yeungnam University, Daegu 42415, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Hwan","family":"Kang","sequence":"additional","affiliation":[{"name":"College of Medicine, Yeungnam University, Daegu 42415, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Ae","family":"Koh","sequence":"additional","affiliation":[{"name":"College of Medicine, Yeungnam University, Daegu 42415, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Hee","family":"Kang","sequence":"additional","affiliation":[{"name":"School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keon Uk","family":"Park","sequence":"additional","affiliation":[{"name":"School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyera","family":"Kim","sequence":"additional","affiliation":[{"name":"School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Yong","family":"Park","sequence":"additional","affiliation":[{"name":"School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/357011a0","article-title":"Coley\u2019s toxins in perspective","volume":"357","author":"Starnes","year":"1992","journal-title":"Nature"},{"key":"ref_2","first-page":"471","article-title":"Coley\u2019s toxin: Historical perspective","volume":"4","author":"Bickels","year":"2002","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13058-019-1210-4","article-title":"Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: A systematic literature review","volume":"21","author":"Li","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Wang, P.F., Chen, Y., Song, S.Y., Wang, T.J., Ji, W.J., Li, S.W., Liu, N., and Yan, C.X. (2017). Immune-Related Adverse Events Associated with Anti-PD-1\/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00730"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zhao, Q., Zhang, J., Xu, L., Yang, H., Liang, N., Zhang, L., Zhang, F., and Zhang, X. (2021). Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.730320"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.7150\/jca.85433","article-title":"PD-1\/PD-L1 Inhibitor\u2014Related Adverse Events and Their Management in Breast Cancer","volume":"15","author":"Lei","year":"2024","journal-title":"J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/0284186X.2022.2106795","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors in triple-negative breast cancer: A systematic review and meta-analysis","volume":"61","author":"Zhang","year":"2022","journal-title":"Acta Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-Line Immunotherapy for Non-Small-Cell Lung Cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study","volume":"42","author":"Motzer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_18","unstructured":"U.S. Department of Health and Human Services (2017). Common Terminology Criteria for Adverse Events (CTCAE), NIH Publication. Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e002597","DOI":"10.1136\/jitc-2021-002597","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer","volume":"9","author":"Emens","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lee, J.S., Yost, S.E., and Yuan, Y. (2020). Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges. Cancers, 12.","DOI":"10.3390\/cancers12061404"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e390464","DOI":"10.1200\/EDBK_390464","article-title":"Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between","volume":"43","author":"Han","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: Exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.21037\/atm-20-4750","article-title":"The dark side of immunotherapy","volume":"9","author":"Okwundu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Vaddepally, R., Doddamani, R., Sodavarapu, S., Madam, N.R., Katkar, R., Kutadi, A.P., Mathew, N., Garje, R., and Chandra, A.B. (2022). Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge. Biomedicines, 10.","DOI":"10.3390\/biomedicines10040790"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Wang, X., Qu, J., Zuo, W., Tang, Y., Zhu, H., and Chen, X. (2021). Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.708195"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10732748221130576","DOI":"10.1177\/10732748221130576","article-title":"A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors","volume":"29","author":"Hata","year":"2022","journal-title":"Cancer Control"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s10147-023-02406-x","article-title":"Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: Immortal time bias-corrected analysis","volume":"28","author":"Washino","year":"2023","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"735.e9","DOI":"10.1016\/j.urolonc.2021.05.012","article-title":"Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab","volume":"39","author":"Ikeda","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clgc.2023.09.007","article-title":"Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated with Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study","volume":"22","author":"Nukaya","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-132-4-200002150-00004","article-title":"Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study","volume":"132","author":"Hak","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_34","first-page":"267","article-title":"The Biological Disappearance Rate of Prothrombin, Factors VII, IX and X from Plasma in Hypothyroidism, Hyperthyroidism, and During Fever","volume":"10","author":"Loeliger","year":"1964","journal-title":"Thromb. Diath. Haemorrh."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4103\/ijem.IJEM_583_17","article-title":"Study on Coagulation Factor VIII and Fibrinogen Levels in Patients with Thyroid Disorders","volume":"22","author":"Thoyyib","year":"2018","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.0954-6820.1983.tb03724.x","article-title":"Long QT interval and ventricular tachycardia of \u201ctorsade de pointe\u201d type in hypothyroidism","volume":"213","author":"Fredlund","year":"1983","journal-title":"Acta Med. Scand."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.14797\/mdcj-13-2-55","article-title":"Hypothyroidism and the Heart","volume":"13","author":"Udovcic","year":"2017","journal-title":"Methodist. Debakey Cardiovasc. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM200102153440707","article-title":"Thyroid hormone and the cardiovascular system","volume":"344","author":"Klein","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.106.678326","article-title":"Thyroid disease and the heart","volume":"116","author":"Klein","year":"2007","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kahaly, G.J. (2021). Administration and Pharmacokinetics of Levothyroxine. 70 Years of Levothyroxine, Springer.","DOI":"10.1007\/978-3-030-63277-9"},{"key":"ref_41","first-page":"40","article-title":"A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism","volume":"9","author":"Colucci","year":"2013","journal-title":"Eur. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101926","DOI":"10.1016\/j.eclinm.2023.101926","article-title":"Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: A cross-sectional analysis","volume":"58","author":"Martin","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41590-021-01058-1","article-title":"Human immune diversity: From evolution to modernity","volume":"22","author":"Liston","year":"2021","journal-title":"Nat. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/919\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:17:49Z","timestamp":1773465469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/6\/919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["cancers18060919"],"URL":"https:\/\/doi.org\/10.3390\/cancers18060919","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}